STOCK TITAN

[Form 4] Ralph Lauren Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 highlights: On 31 Jul 2025, Clover Health (CLOV) officer Conrad Wai had 27,930 Class A shares withheld at $2.89 (Code F) to satisfy tax on the vesting of 12.5 % of an RSU grant dated 31 Oct 2023. The withheld amount equals roughly 1.7 % of his direct stake.

Post-transaction holdings: Wai still controls 1,671,837 shares directly and 1,403,701 shares indirectly through a family trust—about 3.08 M shares in total—so economic exposure remains virtually unchanged.

Investor takeaway: Because the disposition is automatic, not an open-market trade, it conveys no bearish signal. Remaining RSUs continue to vest quarterly until 31 Oct 2025, maintaining long-term alignment between the executive and shareholders. Market impact is expected to be minimal.

Punti salienti del Modulo 4: Il 31 luglio 2025, l'incaricato di Clover Health (CLOV), Conrad Wai, ha trattenuto 27.930 azioni di Classe A a $2,89 (Codice F) per coprire le tasse relative al maturare del 12,5% di una concessione RSU datata 31 ottobre 2023. L'importo trattenuto corrisponde a circa l'1,7% della sua partecipazione diretta.

Detenzione post-transazione: Wai detiene ancora direttamente 1.671.837 azioni e indirettamente 1.403.701 azioni tramite un trust familiare—per un totale di circa 3,08 milioni di azioni—quindi l'esposizione economica rimane praticamente invariata.

Considerazioni per gli investitori: Poiché la disposizione è automatica e non una vendita sul mercato aperto, non rappresenta un segnale ribassista. Le RSU rimanenti continueranno a maturare trimestralmente fino al 31 ottobre 2025, mantenendo un allineamento a lungo termine tra il dirigente e gli azionisti. L'impatto sul mercato è previsto minimo.

Aspectos destacados del Formulario 4: El 31 de julio de 2025, el ejecutivo de Clover Health (CLOV), Conrad Wai, tuvo retenidas 27,930 acciones Clase A a $2.89 (Código F) para cubrir impuestos por la consolidación del 12.5% de una concesión de RSU fechada el 31 de octubre de 2023. La cantidad retenida equivale aproximadamente al 1.7% de su participación directa.

Posición tras la transacción: Wai aún controla directamente 1,671,837 acciones y 1,403,701 acciones indirectamente a través de un fideicomiso familiar, sumando un total de aproximadamente 3.08 millones de acciones, por lo que la exposición económica permanece prácticamente sin cambios.

Conclusión para inversores: Dado que la disposición es automática y no una operación en el mercado abierto, no transmite una señal bajista. Las RSU restantes continúan consolidándose trimestralmente hasta el 31 de octubre de 2025, manteniendo la alineación a largo plazo entre el ejecutivo y los accionistas. Se espera un impacto mínimo en el mercado.

Form 4 주요 내용: 2025년 7월 31일, Clover Health(CLOV) 임원 Conrad Wai는 2023년 10월 31일에 부여된 RSU의 12.5%가 취득됨에 따라 세금 납부를 위해 $2.89(코드 F) 가격으로 27,930주 클래스 A 주식을 원천징수했습니다. 원천징수된 주식 수는 그의 직접 지분의 약 1.7%에 해당합니다.

거래 후 보유 현황: Wai는 여전히 직접 1,671,837주, 가족 신탁을 통해 간접적으로 1,403,701주를 보유하고 있어 총 약 308만 주를 보유 중이며, 경제적 노출은 사실상 변함이 없습니다.

투자자 참고 사항: 처분이 자동으로 이루어지는 것이며 공개 시장에서의 거래가 아니기 때문에 약세 신호를 나타내지 않습니다. 남은 RSU는 2025년 10월 31일까지 분기별로 계속 취득되며, 임원과 주주 간 장기적인 이해관계 일치를 유지합니다. 시장에 미치는 영향은 미미할 것으로 예상됩니다.

Points clés du formulaire 4 : Le 31 juillet 2025, l'officier de Clover Health (CLOV), Conrad Wai, a fait retenir 27 930 actions de classe A à 2,89 $ (code F) pour couvrir l'impôt lié à la levée de 12,5 % d'une attribution de RSU datée du 31 octobre 2023. Le montant retenu correspond à environ 1,7 % de sa participation directe.

Détention après la transaction : Wai contrôle toujours directement 1 671 837 actions et indirectement 1 403 701 actions via un trust familial — soit environ 3,08 millions d'actions au total — donc son exposition économique reste pratiquement inchangée.

À retenir pour les investisseurs : Comme la cession est automatique et non une vente sur le marché libre, elle ne constitue pas un signal baissier. Les RSU restantes continueront à se libérer trimestriellement jusqu'au 31 octobre 2025, maintenant ainsi un alignement à long terme entre le dirigeant et les actionnaires. L'impact sur le marché devrait être minimal.

Formular 4 Highlights: Am 31. Juli 2025 wurden von Clover Health (CLOV) Vorstand Conrad Wai 27.930 Class-A-Aktien zu 2,89 $ (Code F) einbehalten, um die Steuer auf die Freigabe von 12,5 % einer RSU-Zuteilung vom 31. Oktober 2023 zu begleichen. Die einbehaltene Menge entspricht etwa 1,7 % seines direkten Anteils.

Bestände nach der Transaktion: Wai hält weiterhin direkt 1.671.837 Aktien und indirekt 1.403.701 Aktien über einen Familientrust – insgesamt rund 3,08 Millionen Aktien – sodass die wirtschaftliche Beteiligung praktisch unverändert bleibt.

Fazit für Investoren: Da die Veräußerung automatisch erfolgt und kein Handel am offenen Markt ist, stellt dies kein bärisches Signal dar. Die verbleibenden RSUs werden weiterhin vierteljährlich bis zum 31. Oktober 2025 freigegeben und sorgen für eine langfristige Ausrichtung zwischen dem Vorstand und den Aktionären. Die Marktauswirkungen werden voraussichtlich minimal sein.

Positive
  • Executive retains roughly 3.08 M shares, underscoring sustained equity alignment with shareholders.
Negative
  • 27,930 shares were disposed of (withheld) to cover taxes, modestly increasing share count dilution, though immaterial to investors.

Insights

TL;DR: Tax-withholding disposition; no sentiment change, negligible impact.

The Code F transaction merely covers withholding taxes on RSU vesting. Wai’s aggregate ownership stays above 3 M shares, so insider exposure is intact. The withheld 27,930 shares represent <1 % of CLOV’s average daily volume and 0.08 % of shares outstanding—too small to move the stock. No bullish or bearish inference should be drawn.

TL;DR: Routine compliance event; alignment with shareholders preserved.

The filing demonstrates proper Section 16 reporting and a standard tax-settlement mechanism. Continued vesting through Oct 2025 incentivizes performance. No red flags on governance or insider confidence arise from this disclosure.

Punti salienti del Modulo 4: Il 31 luglio 2025, l'incaricato di Clover Health (CLOV), Conrad Wai, ha trattenuto 27.930 azioni di Classe A a $2,89 (Codice F) per coprire le tasse relative al maturare del 12,5% di una concessione RSU datata 31 ottobre 2023. L'importo trattenuto corrisponde a circa l'1,7% della sua partecipazione diretta.

Detenzione post-transazione: Wai detiene ancora direttamente 1.671.837 azioni e indirettamente 1.403.701 azioni tramite un trust familiare—per un totale di circa 3,08 milioni di azioni—quindi l'esposizione economica rimane praticamente invariata.

Considerazioni per gli investitori: Poiché la disposizione è automatica e non una vendita sul mercato aperto, non rappresenta un segnale ribassista. Le RSU rimanenti continueranno a maturare trimestralmente fino al 31 ottobre 2025, mantenendo un allineamento a lungo termine tra il dirigente e gli azionisti. L'impatto sul mercato è previsto minimo.

Aspectos destacados del Formulario 4: El 31 de julio de 2025, el ejecutivo de Clover Health (CLOV), Conrad Wai, tuvo retenidas 27,930 acciones Clase A a $2.89 (Código F) para cubrir impuestos por la consolidación del 12.5% de una concesión de RSU fechada el 31 de octubre de 2023. La cantidad retenida equivale aproximadamente al 1.7% de su participación directa.

Posición tras la transacción: Wai aún controla directamente 1,671,837 acciones y 1,403,701 acciones indirectamente a través de un fideicomiso familiar, sumando un total de aproximadamente 3.08 millones de acciones, por lo que la exposición económica permanece prácticamente sin cambios.

Conclusión para inversores: Dado que la disposición es automática y no una operación en el mercado abierto, no transmite una señal bajista. Las RSU restantes continúan consolidándose trimestralmente hasta el 31 de octubre de 2025, manteniendo la alineación a largo plazo entre el ejecutivo y los accionistas. Se espera un impacto mínimo en el mercado.

Form 4 주요 내용: 2025년 7월 31일, Clover Health(CLOV) 임원 Conrad Wai는 2023년 10월 31일에 부여된 RSU의 12.5%가 취득됨에 따라 세금 납부를 위해 $2.89(코드 F) 가격으로 27,930주 클래스 A 주식을 원천징수했습니다. 원천징수된 주식 수는 그의 직접 지분의 약 1.7%에 해당합니다.

거래 후 보유 현황: Wai는 여전히 직접 1,671,837주, 가족 신탁을 통해 간접적으로 1,403,701주를 보유하고 있어 총 약 308만 주를 보유 중이며, 경제적 노출은 사실상 변함이 없습니다.

투자자 참고 사항: 처분이 자동으로 이루어지는 것이며 공개 시장에서의 거래가 아니기 때문에 약세 신호를 나타내지 않습니다. 남은 RSU는 2025년 10월 31일까지 분기별로 계속 취득되며, 임원과 주주 간 장기적인 이해관계 일치를 유지합니다. 시장에 미치는 영향은 미미할 것으로 예상됩니다.

Points clés du formulaire 4 : Le 31 juillet 2025, l'officier de Clover Health (CLOV), Conrad Wai, a fait retenir 27 930 actions de classe A à 2,89 $ (code F) pour couvrir l'impôt lié à la levée de 12,5 % d'une attribution de RSU datée du 31 octobre 2023. Le montant retenu correspond à environ 1,7 % de sa participation directe.

Détention après la transaction : Wai contrôle toujours directement 1 671 837 actions et indirectement 1 403 701 actions via un trust familial — soit environ 3,08 millions d'actions au total — donc son exposition économique reste pratiquement inchangée.

À retenir pour les investisseurs : Comme la cession est automatique et non une vente sur le marché libre, elle ne constitue pas un signal baissier. Les RSU restantes continueront à se libérer trimestriellement jusqu'au 31 octobre 2025, maintenant ainsi un alignement à long terme entre le dirigeant et les actionnaires. L'impact sur le marché devrait être minimal.

Formular 4 Highlights: Am 31. Juli 2025 wurden von Clover Health (CLOV) Vorstand Conrad Wai 27.930 Class-A-Aktien zu 2,89 $ (Code F) einbehalten, um die Steuer auf die Freigabe von 12,5 % einer RSU-Zuteilung vom 31. Oktober 2023 zu begleichen. Die einbehaltene Menge entspricht etwa 1,7 % seines direkten Anteils.

Bestände nach der Transaktion: Wai hält weiterhin direkt 1.671.837 Aktien und indirekt 1.403.701 Aktien über einen Familientrust – insgesamt rund 3,08 Millionen Aktien – sodass die wirtschaftliche Beteiligung praktisch unverändert bleibt.

Fazit für Investoren: Da die Veräußerung automatisch erfolgt und kein Handel am offenen Markt ist, stellt dies kein bärisches Signal dar. Die verbleibenden RSUs werden weiterhin vierteljährlich bis zum 31. Oktober 2025 freigegeben und sorgen für eine langfristige Ausrichtung zwischen dem Vorstand und den Aktionären. Die Marktauswirkungen werden voraussichtlich minimal sein.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GEORGE MICHAEL A

(Last) (First) (Middle)
RALPH LAUREN CORPORATION
650 MADISON AVENUE

(Street)
NEW YORK NY 10022

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RALPH LAUREN CORP [ RL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/31/2025 A 581 A (1) 16,142(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of the Issuer's Class A Common Stock issued to the Reporting Person as restricted stock units granted under the Issuer's 2019 Long-Term Stock Incentive Plan. These restricted stock units will vest on July 31, 2026, subject to the Reporting Person's continued service through the 2026 Annual Meeting of Stockholders.
2. The total also reflects a deduction for cash paid in lieu of approximately 0.84 fractional shares of the Issuer's Class A Common Stock upon vesting of previously-granted restricted stock units.
/s/ Avery S. Fischer, Attorney-in-Fact for Michael A. George 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Clover Health shares did Conrad Wai dispose of?

27,930 Class A shares were automatically withheld to pay tax on RSU vesting.

What was the transaction price for CLOV shares?

The shares were valued at $2.89 per share for tax-withholding purposes.

How many CLOV shares does Conrad Wai own after the transaction?

He owns 1,671,837 shares directly and 1,403,701 shares indirectly via a family trust.

Does this Form 4 indicate insider selling pressure on CLOV?

No. The Code F transaction is an automatic tax-withholding event, not an open-market sale.

When will the remaining RSUs vest for Conrad Wai?

The final vesting date for the RSUs is 31 Oct 2025, subject to continued service.
Ralph Lauren

NYSE:RL

RL Rankings

RL Latest News

RL Latest SEC Filings

RL Stock Data

17.79B
37.14M
3.89%
107.28%
2.81%
Apparel Manufacturing
Men's & Boys' Furnishgs, Work Clothg, & Allied Garments
Link
United States
NEW YORK